; and (B) 100 percent of such amount shall be paid not later than 2 years after the date of enactment of this Act. (4) Withdrawal of approval in the case of nonpayment by manufacturer If a manufacturer assessed a fee under this subsection fails to pay the full fee as required under paragraph (3), the Secretary shall withdraw approval of the application under section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 ) for the drug until the fee is paid in full. (5) Investigation Immediately after the date of enactment of this Act, the Secretary, acting through the Commissioner and in consultation with the Attorney General, acting through the Administrator of the Drug Enforcement Administration, shall begin an assessment to set fees under this subsection. (f) Reimbursement of economic impact (1) Establishment of Fund There is established in the Treasury of the United States a fund, to be known as the Opioids Reimbursement Fund (referred to in this subsection as the Fund ), to be administered by the Secretary, in consultation with the Commissioner. (2) Appropriations; transfers to the Fund (A) Appropriation There is appropriated, out of any monies in the Treasury not otherwise appropriated, $20,000,000,000 to the Fund. (B) Transfers In a manner consistent with section 3302(b) of title 31, United States Code, there shall be transferred to the Fund from the General Fund of the Treasury an amount equal to— (i) the amount of the civil penalties collected under subsection (c)